Ethics and Oncology Medworm Feed

Article

Powered by RSS Feed Informer

Recent Videos
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
CRS Recognition and Intervention: Timing and Clinical Features
CRS Recognition and Intervention: Timing and Clinical Features
Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL
Physician Assistant Perspectives: Importance of Patient Shared Decision-Making and Multidisciplinary Team Approach in R/R FL
Physician Assistant Perspectives: Importance of Patient Shared Decision-Making and Multidisciplinary Team Approach in R/R FL
Physician Assistant Perspectives: Aligning Patient Goals in R/R FL and Navigating Third-Line Treatment Options
Physician Assistant Perspectives: Aligning Patient Goals in R/R FL and Navigating Third-Line Treatment Options
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
2 experts in this video
Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
2 experts in this video
First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
Managing Dermatologic Complications in Oncology
Managing Dermatologic Complications in Oncology
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
Related Content
Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

Antonio Llombart-Cussac;José Manuel Pérez-García;Elena Lopez-Miranda;Rui Rui Zhang;Miguel Sampayo-Cordero;Juliana Carvalho-Santos;Olga Boix;Marta Beltran;Carlos Barrios;Guiseppe Curigliano;Rupert Bartsch;Anne Clair Hardy Bessard;Anna Compagnoni;Kathy Puyana Theall;Thomas Buechele;Tomer Wasserman;Javier Cortés, MD
May 28th 2025
Article
Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Russ Conroy
May 28th 2025
Article

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.